|Chemical and physical data|
|Molar mass||361.437 g/mol g·mol−1|
|3D model (JSmol)|
Bradanicline (INN, code name TC-5619) is a drug which was being developed by Targacept that acts as a partial agonist at the α7 subtype of the neural nicotinic acetylcholine receptors. It showed cognitive enhancing effects in animal studies, and was being developed through a collaboration between Targacept and AstraZeneca as a potential treatment for schizophrenia and attention deficit disorder.  Phase I clinical trials were completed successfully, and it was in phase II trials.
In May 2011, AstraZeneca declined to exercise its right to license the compound. In September 2012, Targacept ended its development of badanicline for the purpose of treating ADHD in adults. It was being studied for cognitive and memory enhancement.
- "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 73" (PDF). World Health Organization. pp. 68–9. Retrieved 3 January 2017.
- TC-5619 Cognitive Dysfunction in Schizophrenia Archived August 20, 2008, at the Wayback Machine
- Rethinking Schizophrenia
- Targacept retains full development rights for TC-5619
- Targacept ends development of ADHD drug
- "Statement on a Nonproprietary Name Adopted by the USAN Council" (PDF). November 27, 2013. Cite journal requires
- "Bradanicline - Attenua - AdisInsight".
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|